Acceleration2012.png

Untitled Document

Agenda

 

3:00 – 3:30 p.m.

Registration & Networking

3:30 – 3:50 p.m.

Welcome & Introduction

 

William C. Geary III
Partner, Intellectual Property
Nutter McClennen & Fish

3:50 – 4:15 p.m.

Keynote Speaker

 

Robert S. Langer, Sc.D.
David H. Koch Institute Professor
Massachusetts Institute of Technology

4:15 – 5:15 p.m.

Panel I: Trends in Early-Stage Finance and Deal Structures

 

Moderator:

 

Laurie Halloran
Chief Executive Officer
Halloran Consulting Group

 

Panelists:

 

Omar Amirana, M.D.
Managing Director
Allied Minds

 

Alexis Borisy
Partner
Third Rock Ventures

 

Bill McPhee
Angel Investor
Managing Director, Praxis Advisors

 

Susan R. Windham-Bannister, Ph.D.
President and CEO
Massachusetts Life Sciences Center

 

The amount of venture capital invested in the life sciences sector during the second quarter of 2012 decreased for the fourth consecutive quarter, shrinking by 39% compared to the same period in 2011. In spite of the adverse funding environment, and perhaps because of it, experimentation with innovative early-stage funding models and deal structures is taking place among development-stage life science companies, venture capital funds, and large pharmaceutical and medical device firms.
Our panel of life science venture capitalists and angel investors will explore recent funding collaborations between venture capital and large life science companies, innovative ways to attract investment and generate shareholder returns, the role of non-dilutive capital, and other mechanisms to preserve value for founders and early investors of emerging life sciences companies.

5:15 – 5:30 p.m.

Break

5:30 – 6:30 p.m.

Panel II: Building Blocks of Successful Business Development–Maximizing Value Creation and Attracting Buyers

 

Moderator:

 

Michelle L. Basil
Chair, Life Sciences Group
Nutter McClennen & Fish

 

Panelists:

 

David H. Donabedian, Ph.D.
Senior Vice President
Locust Walk Partners

 

Paul LaViolette
Partner
SV Life Sciences

 

Leslie J. Williams, B.S., R.N., M.B.A.
Chief Executive Officer
ImmusanT

 

Leading a successful life sciences company requires the formulation and execution of a multi-dimensional business development plan. This panel will discuss the key building-blocks for a successful business development strategy that positions a life science company for an attractive exit opportunity. Topics examined will include the importance of clinical strategy, planning for regulatory and reimbursement challenges, negotiating strategic collaborations, and how and when to engage with potential acquirers or partners.

6:30 – 7:30 p.m.

Cocktails & Hors d’oeuvres

 

Click on a thumbnail for
2012 speaker bios.